Published in PLoS One on January 13, 2010
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
A molecular basis for NKT cell recognition of CD1d-self-antigen. Immunity (2011) 1.94
The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res (2015) 0.96
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide. PLoS One (2010) 0.94
The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer Immunol Immunother (2014) 0.93
The Extended Family of CD1d-Restricted NKT Cells: Sifting through a Mixed Bag of TCRs, Antigens, and Functions. Front Immunol (2015) 0.89
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents. Clin Transl Immunology (2016) 0.88
Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy. Cancers (Basel) (2011) 0.79
iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo . Cancer Immunol Res (2014) 0.79
Natural killer T cell based Immunotherapy. J Vaccines Vaccin (2012) 0.77
Tuning cancer fate: the unremitting role of host immunity. Open Biol (2017) 0.75
Antitumor Responses of Invariant Natural Killer T Cells. J Immunol Res (2015) 0.75
Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression. Bone Marrow Transplant (2016) 0.75
Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features. Immunology (2016) 0.75
Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells. Mucosal Immunol (2017) 0.75
The biology of NKT cells. Annu Rev Immunol (2007) 14.43
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A (1995) 8.16
An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med (1994) 7.35
Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol (2005) 7.08
CD1: antigen presentation and T cell function. Annu Rev Immunol (2004) 6.89
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol (2001) 4.91
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res (1997) 3.67
An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J Exp Med (1994) 3.47
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 3.33
Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A (1998) 2.96
Control points in NKT-cell development. Nat Rev Immunol (2007) 2.92
Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med (2005) 2.83
Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol (2009) 2.79
A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med (2002) 2.73
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med (2003) 2.48
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol (2007) 2.46
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest (2008) 2.46
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol (2001) 2.20
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008) 1.99
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest (2009) 1.78
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol (2007) 1.61
Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood (2008) 1.45
Dicer-dependent microRNA pathway controls invariant NKT cell development. J Immunol (2009) 1.41
Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res (2005) 1.40
Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci U S A (2003) 1.35
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol (2005) 1.29
In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J Immunol (1988) 1.29
Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia (2003) 1.28
NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood (2008) 1.28
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res (2008) 1.20
Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer (2004) 1.13
Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol Cell Biol (2004) 1.07
Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother (2005) 1.00
Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Cancer Res (2006) 0.96
Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res (2003) 0.95
Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate (2008) 0.89
Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules? Int J Cancer (2002) 0.86
Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses. J Immunol (2006) 0.78
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst (2004) 4.07
Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Ann Surg (2002) 2.50
High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells. Eur J Immunol (2011) 2.27
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med (2003) 2.01
Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol (2008) 1.98
[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging (2008) 1.96
Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol (2011) 1.91
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med (2002) 1.80
The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer. J Urol (2012) 1.68
Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol (2009) 1.61
The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int (2010) 1.60
Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol (2009) 1.60
Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol (2011) 1.58
Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer (2011) 1.56
Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. J Urol (2011) 1.53
When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy? Int J Urol (2010) 1.52
Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions and predict the malignancy of human tumors. Stem Cells Transl Med (2013) 1.50
Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score. BJU Int (2013) 1.47
Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma. Eur Urol (2011) 1.47
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst (2014) 1.46
Cutting edge: influence of the TCR Vbeta domain on the selection of semi-invariant NKT cells by endogenous ligands. J Immunol (2006) 1.43
Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. Urology (2013) 1.42
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 1.41
Dicer-dependent microRNA pathway controls invariant NKT cell development. J Immunol (2009) 1.41
Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol (2008) 1.32
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol (2005) 1.29
NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood (2008) 1.28
Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol (2012) 1.25
Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol (2003) 1.25
Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions. Cytometry A (2008) 1.24
Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help. J Immunol (2012) 1.22
Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res (2008) 1.20
Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients. J Immunol (2008) 1.18
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol (2012) 1.17
T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol (2002) 1.14
Lipid-protein interactions: biosynthetic assembly of CD1 with lipids in the endoplasmic reticulum is evolutionarily conserved. Proc Natl Acad Sci U S A (2004) 1.13
Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol (2004) 1.12
Targeted expression of human CD1d in transgenic mice reveals independent roles for thymocytes and thymic APCs in positive and negative selection of Valpha14i NKT cells. J Immunol (2005) 1.11
The extent of tumour fat invasion affects survival in patients with renal cell carcinoma and venous tumour thrombosis. BJU Int (2010) 1.10
CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood (2007) 1.09
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol (2012) 1.09
Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med (2008) 1.08
Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol (2004) 1.07
The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function. J Exp Med (2009) 1.06
Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol (2008) 1.06
Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int (2009) 1.05
Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice. J Immunol (2003) 1.04
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol (2002) 1.04
Loss of T cell microRNA provides systemic protection against autoimmune pathology in mice. J Autoimmun (2012) 1.00
Incidental finding of parathyroid adenoma with 11C-choline PET/CT. Clin Nucl Med (2012) 1.00
The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res (2003) 0.99
Fine tuning by human CD1e of lipid-specific immune responses. Proc Natl Acad Sci U S A (2011) 0.98
Leydig cell tumour of the testis: presentation, therapy, long-term follow-up and the role of organ-sparing surgery in a single-institution experience. BJU Int (2008) 0.97
Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores? J Urol (2008) 0.97
Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood (2006) 0.97
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res (2010) 0.95
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res (2003) 0.95
Innate-like effector differentiation of human invariant NKT cells driven by IL-7. J Immunol (2008) 0.94
Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation. PLoS One (2013) 0.94
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. Oncoimmunology (2013) 0.93